Learn more about our solutions for your employees and organization.

By 2035, 1 in 2 Americans Are Projected to Have Cardiovascular Disease

$44,439

is an employer's average per-employee direct cost in the year of a coronary heart disease (CHD) diagnosis or cardiac event

#2

cardiovascular disease now ranks second in claims, ahead of blood cancers

10:1

is the ratio of spend for employees with CHD in the year of diagnosis or event vs. those without CHD

Employers Partner With Us for Differentiated Cardiovascular Solutions

Evidence-Based Blood Tests

Powered by epigenetics and AI, our clinically validated tests help employees uncover their heart attack risk and coronary heart disease under the guidance of a healthcare provider.

Explore Our Tests

Evidence-Based Blood Tests

Ongoing, Unparalleled Support

From rollout to care navigation, we handle logistics, employee engagement, and healthcare provider coordination, ensuring follow-through at every step.

Explore Employee Journey

Real-Time Insights with HeartRisk™

Compliant, population-level insights to help mitigate financial risk, optimize benefits design, and reduce overall healthcare spend.

Explore HeartRisk™

Simple Blood Tests for Your Employees Under the Guidance of a Healthcare Provider

Less than 20% of cardiovascular disease risk is driven by genetics. It is mostly shaped by lifestyle and environment, such as stress, diet, activity, and smoking.

That’s why Cardio Diagnostics’ blood tests go beyond genetics to measure DNA methylation, an epigenetic marker that reflects how lifestyle factors and environmental stressors impact heart health.

Because each person carries a unique combination of genetic and epigenetic signals in their DNA, our tests leverage AI to uncover an individual’s “molecular fingerprint” of heart disease, turning a simple blood draw into actionable clinical insights.

Our Tests

The Epi+Gen CHD™ test combines epigenetic and genetic (DNA methylation) insights with AI analysis to provide a personalized view of heart attack risk. By looking at both inherited DNA and the impact of lifestyle, environment, and behavior, the test reveals risks that traditional risk calculators may miss, even in the absence of common risk factors.

With these insights, employees and their healthcare provider can take proactive steps earlier, helping to prevent costly and devastating cardiac events.

Traditional methods like stress testing and imaging often miss early coronary heart disease (CHD). This can leave patients with false reassurance and delayed treatment. PrecisionCHD™ addresses this gap by using epigenetics, genetics and AI analysis to detect a CHD signal before it may become visible through standard testing. The test delivers a simple result: CHD signal detected or not detected.

The clinical report is paired with an Actionable Clinical Intelligence™ (ACI) report which shows how each patient’s unique biomarkers is linked to certain disease pathways. This gives healthcare providers clinical context and evidence-based insights for next steps, whether that be additional diagnostics, targeted therapies, or proactive monitoring.

Traditional Testing vs. Precision Medicine Solutions

Test Type

What It Looks At

Limitations

How Cardio Diagnostics Fills the Gap

Traditional Risk Factors

Risk factors such as blood pressure, lipid, and HbA1c

50% of those who had a cardiac event or coronary heart disease did not have any traditional risk factors

Analyzes both genetic and epigenetic factors to reveal underlying risk, even when traditional factors may look normal

Coronary Calcium Score

Quantifies calcified plaque in coronary arteries

One-fourth to one-third of those with incident cardiovascular disease have a zero calcium score

Identifies unique biological risk profile regardless of the presence of calcified plaques

Electrophysiological

Measures the heart's electrical activity to identify abnormalities

Low sensitivity and does not help elucidate drivers of disease for personalized treatment and management

Detects early disease/risk biology, before signs and symptoms may appear and elucidates disease drivers

Imaging

Invasive and radiation-based testing that visualizes structural and functional changes in the heart and arteries, often detecting obstructive CHD after it has developed

A form of CHD called INOCA (ischemia with no obstructive coronary arteries), which would evade detection with these tests, affects 30-65% of patients referred for diagnostic coronary angiography

Non-invasive, radiation-free and captures the unique molecular underpinnings of coronary heart disease, allowing the detection of both obstructive and non-obstructive presentations

A Simple Journey to Help Your Employees Stay Ahead of Cardiovascular Disease

We partner with you to deliver custom communications such as emails, direct mailers, posters, webinars, landing pages and more to build employee awareness and education of our tests while driving proactive participation in testing.

The appropriate test will be ordered by a licensed healthcare provider. We can partner with your onsite or nearsite clinic and/or provide a telemedicine option through our partner for a fully virtual experience. Test results are returned to the ordering provider within 10 business days.

Once a test is ordered, a blood sample can be collected at the onsite or nearsite clinic using collection kits we provide, an onsite heart health event we host, and/or send an at-home finger stick collection kit directly to the employee.

After test results are available, if consented, a Cardio Diagnostics Care Navigator will reach out to the employee to offer personalized support and resources. This includes sharing educational resources, finding an in-network provider or specialist, and connecting the employee to relevant benefits available through their employer.

HeartRisk™ Helps Turn Real-Time Insights Into Action

HeartRisk™ is our HIPAA compliant, real-time reporting platform that transforms cardiovascular risk data into actionable insights. It merges anonymized employee results from our tests, Epi+Gen CHD™ and PrecisionCHD™, with industry and geographic benchmarks to give employers a clear view of their employee population’s heart health.

Risk Assessment and Detection Dashboard

Visualize heart disease risk across your employee population with clear, easy-to-interpret dashboards.

Risk Assessment and Detection Dashboard

Segmentation and Benchmarking

Break down risk by demographics, location, or industry to uncover patterns and target programs.

Longitudinal Insights

Track changes in heart disease risk over time to measure the impact of health programs, preventive strategies and cardiovascular spend.

Compliance and Privacy

All data is HIPAA-compliant and aggregated to protect individual privacy.

While Epi+Gen CHD™ and PrecisionCHD™ provide powerful individual-level insights for employees and their healthcare provider to take action, HeartRisk™ scales those insights to the population level for leadership to inform risk mitigation strategies. Helping your organization to:

Invest strategically in wellness and disease-prevention programs

Reduce costly
cardiovascular claims

Improve employee satisfaction and productivity

Partner With Cardio Diagnostics to Protect Your Employees While Reducing Healthcare Spend

Request a Demo

Frequently Asked Questions

Cardiovascular disease is the leading cause of death and disability in US and one of the most expensive conditions to manage. Offering Epi+Gen CHD™ (a three-year heart attack risk assessment) and PrecisionCHD™ (a diagnostic aid for coronary heart disease) gives employees access to early, non-invasive testing. This helps prevent unexpected cardiac events, reduces high-cost claims, and demonstrates your company’s commitment to employee health and well-being.

Epi+Gen CHD™ identifies employees at high risk for a heart attack or sudden cardiac death up to three years in advance, even when cholesterol and blood pressure look normal. PrecisionCHD™ helps detect existing coronary heart disease at the molecular level, before major symptoms or events may occur. Together, they empower employees to take preventive action, resulting in healthier, more productive workforces.

A single cardiac hospitalization can cost tens of thousands of dollars. By catching hidden risk and better managing disease, employers can reduce avoidable emergency events, lower claims costs, and minimize absenteeism. These savings directly benefit self-funded employers and contribute to long-term ROI.

Yes. Employees have several options to access our tests, including telehealth appointments, onsite heart health fairs, and onsite or nearsite clinics where available. Sample collection is simple and convenient, either through a standard blood draw (venipuncture) at a fair or clinic, or with a finger-stick kit that allows a small blood sample to be collected at home and mailed back. Both methods require no fasting and involve no radiation exposure.

The retail price is $350 for Epi+Gen CHD™ and $850 for PrecisionCHD™. PrecisionCHD™. Employers implementing testing at scale may qualify for custom pricing. Some employees may use FSA/HSA funds.

Both. Many cardiac events happen in employees who appeared 'low risk' or with no known risk factors. The right test will ultimately be selected by a healthcare provider based on the employee's health questionnaire, risk factors, symptoms and other available information.

Cardio Diagnostics, Inc. Internal Claims Data Analysis.
Sun Life Releases Annual Report on Highest-Cost Medical Claims; Cardiovascular Disease Rises to Second Place. Sun Life. Accessed September 8, 2025. sunlife.com/news-release
Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860-1870. doi:10.1016/j.jacc.2006.10.079
Blaha MJ, Cainzos-Achirica M, Greenland P. Zero Coronary Artery Calcium Score: Desirable, But Enough? Circulation. 2020;142(9):917–919. doi:10.1161/CIRCULATIONAHA.119.045026
Bastiany, A., Pacheco, C., Sedlak, T., Saw, J., Miner, S. E. S., Liu, S., Lavoie, A., Kim, D. H., Gulati, M., & Graham, M. M. (2022). A practical approach to invasive testing in ischemia with no obstructive coronary arteries (INOCA). CJC Open, 4(8), 709-720. https://doi.org/10.1016/j.cjco.2022.04.009